The application for the renewal of the approval of the active substance beflubutamid was submitted on 27 November 2014 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 12 December 2019 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 10 November 2023, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 16 December 2024 and 14 February 2025. On 6 October 2025, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 5 November 2025 within the deadline given. On 17 June 2026, the rapporteur Member State submitted the revised draft renewal assessment report to the Authority. If no additional information pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012 is requested, the Authority estimates that it will be able to finalise its conclusion for beflubutamid by the end of March 2027, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 21 months, until 31 July 2028.
Recital 24, Regulation (EU) 2026/1826
In forcesince 28 Jul 2026
- celex=32012R0844